443 related articles for article (PubMed ID: 26143635)
1. Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials.
Mai R; Zhou S; Zhong W; Rong S; Cong Z; Li Y; Xie Q; Chen H; Li X; Liu S; Cheng Y; Huang Y; Zhou Y; Zhang G
Oncotarget; 2015 Sep; 6(29):28502-12. PubMed ID: 26143635
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials.
Liu M; Yang X; Liu J; Zhao B; Cai W; Li Y; Hu D
Oncotarget; 2017 May; 8(19):32258-32269. PubMed ID: 28416755
[TBL] [Abstract][Full Text] [Related]
3. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
Devji T; Levine O; Neupane B; Beyene J; Xie F
JAMA Oncol; 2017 Mar; 3(3):366-373. PubMed ID: 27787543
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta-analysis and systematic review.
Yu Q; Xie J; Li J; Lu Y; Liao L
Cancer Med; 2019 Sep; 8(12):5414-5424. PubMed ID: 31393083
[TBL] [Abstract][Full Text] [Related]
5. Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma.
Consoli F; Bersanelli M; Perego G; Grisanti S; Merelli B; Berruti A; Petrelli F
Clin Transl Oncol; 2020 Jun; 22(6):900-907. PubMed ID: 31555967
[TBL] [Abstract][Full Text] [Related]
6. Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma.
Schmitt RJ; Kreidler SM; Glueck DH; Amaria RN; Gonzalez R; Lewis K; Bagrosky BM; Kwak JJ; Koo PJ
Nucl Med Commun; 2016 Feb; 37(2):122-8. PubMed ID: 26440571
[TBL] [Abstract][Full Text] [Related]
7. Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis.
Pala L; De Pas T; Pagan E; Minucci S; Catania C; Digiacomo N; Cocorocchio E; Laszlo D; Di Muzio A; Barigazzi C; Stucchi E; De Grandi L; Stucchi S; Viale G; Gelber RD; Bagnardi V; Conforti F
Semin Oncol; 2023; 50(1-2):34-39. PubMed ID: 36967333
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis.
Pasquali S; Chiarion-Sileni V; Rossi CR; Mocellin S
Cancer Treat Rev; 2017 Mar; 54():34-42. PubMed ID: 28189914
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy of melanoma using kinase inhibitors.
Heppt MV; Tietze JK; Graf SA; Berking C
Curr Opin Oncol; 2015 Mar; 27(2):134-40. PubMed ID: 25602684
[TBL] [Abstract][Full Text] [Related]
10. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
[TBL] [Abstract][Full Text] [Related]
11. BRAF and MEK inhibition in melanoma.
Dossett LA; Kudchadkar RR; Zager JS
Expert Opin Drug Saf; 2015 Apr; 14(4):559-70. PubMed ID: 25648338
[TBL] [Abstract][Full Text] [Related]
12. TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.
Thielmann CM; Matull J; Zaremba A; Murali R; Chorti E; Lodde G; Jansen P; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Kretz J; Möller I; Sucker A; Paschen A; Livingstone E; Zimmer L; Hadaschik E; Ugurel S; Schadendorf D; Griewank KG
Eur J Cancer; 2022 Jan; 161():99-107. PubMed ID: 34936949
[TBL] [Abstract][Full Text] [Related]
13. Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors.
Kahn AM; Perry CJ; Etts K; Kluger H; Sznol M
Oncologist; 2024 Apr; 29(4):e507-e513. PubMed ID: 37971411
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy of BRAF inhibitors for advanced melanoma with BRAF V600 mutation: a systematic review and meta-analysis.
Kim S; Kim HT; Suh HS
J Dermatolog Treat; 2018 May; 29(3):314-321. PubMed ID: 28504036
[TBL] [Abstract][Full Text] [Related]
15. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings.
Broman KK; Dossett LA; Sun J; Eroglu Z; Zager JS
Expert Opin Drug Saf; 2019 May; 18(5):381-392. PubMed ID: 30977681
[TBL] [Abstract][Full Text] [Related]
16. Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma.
Zoratti MJ; Devji T; Levine O; Thabane L; Xie F
Cancer Treat Rev; 2019 Mar; 74():43-48. PubMed ID: 30798169
[TBL] [Abstract][Full Text] [Related]
17. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.
Simeone E; Grimaldi AM; Festino L; Vanella V; Palla M; Ascierto PA
BioDrugs; 2017 Feb; 31(1):51-61. PubMed ID: 28058658
[TBL] [Abstract][Full Text] [Related]
18. The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis.
Chen P; Chen F; Zhou B
Cutan Ocul Toxicol; 2019 Jun; 38(2):105-111. PubMed ID: 30501438
[TBL] [Abstract][Full Text] [Related]
19. Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.
Puzanov I; Ribas A; Robert C; Schachter J; Nyakas M; Daud A; Arance A; Carlino MS; O'Day SJ; Long GV; Margolin KA; Dummer R; Schadendorf D; Lutzky J; Ascierto PA; Tarhini A; Lin J; Mogg R; Homet Moreno B; Ibrahim N; Hamid O
JAMA Oncol; 2020 Aug; 6(8):1256-1264. PubMed ID: 32672795
[TBL] [Abstract][Full Text] [Related]
20. Trametinib in metastatic melanoma.
Chopra N; Nathan PD
Expert Rev Anticancer Ther; 2015; 15(7):749-60. PubMed ID: 26107021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
